Not known Factual Statements About ABBV-744 preclinical studies and results
In Segment C, participants will get ABBV-744 and oral navitoclax. In Segment D, members will receive ABBV-744 and ruxolitinib. Individuals will receive treatment until eventually ailment progression or the individuals are unable to tolerate the study drugs.- Participant eaten grapefruit or grapefruit products and solutions within three days prior t